Biopeople

Dr. Vaccine

Dr. Vaccine

17.11.2014 - French specialty vaccine developer Abivax has appointed Karl Birth­istle as Vice President Global Regulatory Affairs. At the same time, his colleague Daniel Kenny was named Chief Commercial Officer & VP of Business Development at the firm.

A physician by trade, Birthistle moved sideways into the pharma and biotech industries, where he has held positions focussing on drug, biologics and vaccines development, working at British SmithKlineBeecham, Dutch Pharming, Austrian Baxter Bio­Science and other firms. His most recent post was as Director of Clinical Development and Safety Assessments for Philip Morris in Switzerland. Birthistle remains Deputy Head of the Clinical Review Division of Swissmedic, the Swiss regulatory authority.

http://www.european-biotechnology-news.com/people/bio-people/2014/karl-birthistle.html

23.09.2014 Reneuron Group, a leading UK-based stem cell therapy company, has appointed Olav Hellebø as their new Chief Executive Officer.

© Reneuron

A highly experienced pharmaceutical executive, Hellebø has broad commercial experience gained at both major pharmaceutical and small biotechnology companies in the fields of clinical development, commercialism and marketing of new therapeutics. Before taking on the role of CEO at ReNeuron, Hellebø held the position of CEO at Clavis Pharma ASA, a Norwegian company specialising in oncology. Prior to Clavis, Hellebø was at the helm of UCB Pharma and head of the UK operations of Novartis. Hellebø began his pharmaceutical career in 1992 at Schering-Plough, where he held senior commercial roles in Europe and the US.

22.09.2014 Frank Ubags has joined Cevec Pharmaceuticals to lead its new CMO initiative.

© Cevec Pharmaceuticals

He will replace Rainer Lichtenberger as Managing Director and will channel the extension of Cevec’s offerings to customers and production of up to Phase II cGMP material in CAP cells. Ubags has served more than 35 years in senior positions at firms that include Rhein Biotech, Kiadis Pharma and Scil Proteins. Ubags managed Scil Proteins CMO activities, and also initiated the sale of Scil Proteins Production to Wacker Biotech.

16.09.2014 David Veitch has been appointed as Chief Commercial Officer of Basilea Pharmaceutica International Ltd.

© Basilea Pharmaceutica Ltd.

As a member of the management committee, David Veitch will be responsible for leading Basilea's commercial operations, including sales, marketing, pricing and market access. Veitch has over 25 years of international commercial experience in the pharmaceutical industry. Before joining Basilea, he led cross-functional organisations at the country and European level and was responsible for the launch of numerous brands across several therapeutic areas. From 1996 ­to 2011, he was President European Operations at Savient Pharmaceuticals. Veitch has also held various positions at Bristol-Myers Squibb UK and Europe. His last position at the company was Senior Vice President Europe, Middle-East and Asia, Marketing and Brand Commercialization, where he led the commercial organisation for the region with a focus on specialty care brands.

15.09.2014 Nektarios Tavernarakis, notable researcher with a focus on cell death, neurodegeneration and aging, has been elected a member of The Academy of Europe (Academia Europaea).

© Academia Europaea

Tavernakis is Research Director at the Institute of Molecular Biology and Biotechnology (IMBB) of the Foundation of Research and technology Hellas (FORTH), and professor at the Medical School of the University of Crete, has been elected a member of the Academy of Europe (Academia Europaea). Tavernarakis’ research focuses on cell death, neurodegeneration and ageing. He has received several notable scientific prizes for his scientific accomplishments. Among his accolades are the Academic Excellence Prize from the Empeirikeion Foundation and the Science Excellence Award, General Secretariat for Research and Technology, Ministry of Education both awarded in Greece in 2012. Before joining IMBB-FORTH as Executive Researcher in 2001, Tavernarakis worked as a Research Associate at Rutgers University, USA. Tavernarakis is also an elected member of EMBO.

04.09.2014 Miriam Monge has been named Director of Marketing for pharma and biotech supplier Sartorius Stedim Biotech’s Integrated Solutions unit.

© Sartorius Stedim Biotech

Monge makes the switch from UK consultancy Biopharm Services where she acted as Vice President of Sales & Marketing. She is a committee member of the International Society for Pharmaceutical Engineering (ISPE) and one of the founders of the Global Disposable Community of Practice.

02.09.2014 The former Chair of the Supervisory Board of Dutch clinical-stage immunotherapy company ISA Pharmaceuticals B.V., Ronald Loggers will in the future head the company's daily business activities as CEO.

© ISA Pharmaceuticals

Once Managing Director of ISA’s investor Multi­fund B.V., Loggers took over as acting CEO in June. The new Chief Executive, who holds an MBA from INSEAD and an M.Sc. in Chemical Engineering from the Delft University of Technology, has served on boards in the past, and was Managing Director at Pearle Benelux. Prior to that, he worked for McKinsey & Company and Fokker Aircraft.

28.08.2014 Long-time CEO of Santen Inc. Adrienne Graves has joined the Board of Directors at French ophthalmic company Nicox S.A.

© Nicox

In tandem with Luzi von Bidder and Les Kaplan, who are also freshly appointed to the Board, Graves will be replacing Vaughn Kailian and Vince Anido, who are both stepping down. Before taking on duties as President and CEO at Santen – the US arm of Japan's largest ophthalmic pharmaceutical company – Graves spent nine years with Alcon Laboratories, where her roles included that of Director of International Ophthal­mology. She currently serves as Director on several corporate boards, among them Akorn Inc., TearLab Corporation, Aerpio, Encore Vision and Envisia Therapeutic.

25.08.2014 Gene and cell therapy company Oxford Biomedica plc has appointed Paul Blake as Chief Development Officer.

© Oxford Biomedica

Most recently, Paul was Senior Vice President and Chief Medical Officer of Æterna Zentaris Inc., a Canada-based biopharmaceutical company focused on oncology and endocrine therapy, from 2006 to 2014. Paul was a Member of the Board at Memory Pharmaceutical, Inc. and founding Board member of Protez Pharmaceuticals, which were later acquired by Roche and Novartis, respectively. He was also Director of ViaCell and held senior management positions at Cephalon Inc. He is a fellow of the Royal College of Physicians, a fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians and also a fellow of the American College of Clinical Pharmacology.

Effective September 1st, Blake will take over responsibility for the clinical development of Oxford Biomedica’s therapy pipeline. Blake will also remain a member of the company’s board, which he joined in early 2010.

22.08.2014 Alex Blanchard has taken over the lead for the Microscopy Group of Reading Scientific Services Ltd (RSSL), a analytical service provider to the global food, drink, pharmaceutical and healthcare sectors.

© RSSL

Blanchard was previously Group Analytical and Microbiology Manager at Rentokil Initial. Prior to that he led Procter & Gamble's European Microbiology Department, where he oversaw microbiology risk management for a wide range of products. He was also Global Microbiology Leader for Visualisation and Demos using the latest microscopy capabilities.

As RSSL's Senior Group Leader of Microscopy, Blanchard will head the section using microscopy techniques for projects in new product development.

21.08.2014 Swedish pharmaceutical company Medivir has a new president and CEO: board member Niklas Prager is succeeding Maris Hartmanis effective September 1st.

© Medivir

Prager has long experience of senior executive positions in trade and industry - both as CEO and as board member. He is currently chairman of the board of Qbtech AB and a member of the board of Egain Group AB. Before that, he was chairman of the boards of Biophausia AB, Envirotainer AB and Michael Berglund Search Group AB. He has also served as the CEO of Pfizer AB, Envirotainer AB and Qbtech AB. Stockholm-based Medivir expects a strong contribution to the company's strategic business development and commercialisation of its product portfolio. Prager commented: "An update of Medivir’s strategic plan is the number one priority, and work on this is already well under way."

Vorherige Seite2/22Nächste Seite

Print Magazine

Product of the week

Products

Events

All Events

Stock list

All quotes

TOP

  • FORMYCON10.43 EUR7.08%
  • EVOTEC3.27 EUR4.47%
  • MORPHOSYS78.71 EUR1.88%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • 4SC0.89 EUR-5.32%
  • CYTOS0.28 CHF-3.45%

TOP

  • CYTOS0.28 CHF75.0%
  • EPIGENOMICS5.14 EUR45.6%
  • FORMYCON10.43 EUR32.9%

FLOP

  • THERAMETRICS0.07 CHF-12.5%
  • BIOFRONTERA2.54 EUR-12.4%
  • CO.DON2.50 EUR-9.1%

TOP

  • SANTHERA92.25 CHF2738.5%
  • CO.DON2.50 EUR150.0%
  • BB BIOTECH183.00 EUR63.4%

FLOP

  • CYTOS0.28 CHF-91.7%
  • 4SC0.89 EUR-49.1%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 24.11.2014

Current issue

All issues